NTLA
Price
$12.21
Change
+$0.13 (+1.08%)
Updated
Dec 20, 04:59 PM (EDT)
61 days until earnings call
RGNX
Price
$7.62
Change
+$0.21 (+2.83%)
Updated
Dec 20, 04:59 PM (EDT)
73 days until earnings call
Ad is loading...

NTLA vs RGNX

Header iconNTLA vs RGNX Comparison
Open Charts NTLA vs RGNXBanner chart's image
Intellia Therapeutics
Price$12.21
Change+$0.13 (+1.08%)
Volume$70.18K
CapitalizationN/A
REGENXBIO
Price$7.62
Change+$0.21 (+2.83%)
Volume$65.68K
CapitalizationN/A
NTLA vs RGNX Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. RGNX commentary
Dec 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and RGNX is a Hold.

COMPARISON
Comparison
Dec 22, 2024
Stock price -- (NTLA: $12.21 vs. RGNX: $7.63)
Brand notoriety: NTLA and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 129% vs. RGNX: 901%
Market capitalization -- NTLA: $1.24B vs. RGNX: $378.03M
NTLA [@Biotechnology] is valued at $1.24B. RGNX’s [@Biotechnology] market capitalization is $378.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, both NTLA and RGNX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 4 bearish.
  • RGNX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than RGNX.

Price Growth

NTLA (@Biotechnology) experienced а -5.35% price change this week, while RGNX (@Biotechnology) price change was -7.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 20, 2025.

RGNX is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.24B) has a higher market cap than RGNX($378M). RGNX (-57.493) and NTLA (-59.954) have similar YTD gains . RGNX has higher annual earnings (EBITDA): -217.82M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. RGNX (255M). RGNX has less debt than NTLA: RGNX (84.1M) vs NTLA (102M). RGNX has higher revenues than NTLA: RGNX (84.3M) vs NTLA (43.1M).
NTLARGNXNTLA / RGNX
Capitalization1.24B378M329%
EBITDA-527.52M-217.82M242%
Gain YTD-59.954-57.493104%
P/E RatioN/AN/A-
Revenue43.1M84.3M51%
Total Cash658M255M258%
Total Debt102M84.1M121%
FUNDAMENTALS RATINGS
NTLA vs RGNX: Fundamental Ratings
NTLA
RGNX
OUTLOOK RATING
1..100
6869
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
9292
P/E GROWTH RATING
1..100
10026
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (30) in the Biotechnology industry is somewhat better than the same rating for RGNX (74). This means that NTLA’s stock grew somewhat faster than RGNX’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that NTLA’s stock grew similarly to RGNX’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as RGNX (98). This means that NTLA’s stock grew similarly to RGNX’s over the last 12 months.

NTLA's Price Growth Rating (92) in the Biotechnology industry is in the same range as RGNX (92). This means that NTLA’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (26) in the Biotechnology industry is significantly better than the same rating for NTLA (100). This means that RGNX’s stock grew significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLARGNX
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 13 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ASRFX7.860.11
+1.42%
Invesco Global Real Estate Income R6
STREX21.920.26
+1.20%
Sterling Capital Equity Income R6
ITCSX29.040.21
+0.73%
VY® T. Rowe Price Capital Apprec S
TARKX28.850.06
+0.21%
Tarkio
CLPCX12.12N/A
N/A
Catalyst Nasdaq-100 Hedged Equity C

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+1.08%
VCYT - NTLA
69%
Closely correlated
+4.66%
EDIT - NTLA
68%
Closely correlated
-2.24%
BEAM - NTLA
66%
Loosely correlated
+8.16%
CRSP - NTLA
62%
Loosely correlated
+0.83%
PRME - NTLA
59%
Loosely correlated
+4.66%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with BEAM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+2.97%
BEAM - RGNX
49%
Loosely correlated
+8.16%
DNLI - RGNX
49%
Loosely correlated
-0.14%
AXON - RGNX
48%
Loosely correlated
+2.59%
CRSP - RGNX
45%
Loosely correlated
+0.83%
NTLA - RGNX
44%
Loosely correlated
+1.08%
More